Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $1,380,600.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $69.03, for a total transaction of $1,380,600.00. Following the transaction, the chief executive officer directly owned 733,719 shares of the company’s stock, valued at approximately $50,648,622.57. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Helen Torley also recently made the following trade(s):

• On Wednesday, October 1st, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $75.35, for a total transaction of $1,507,000.00.
• On Wednesday, September 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $74.44, for a total transaction of $1,488,800.00.
• On Tuesday, August 12th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $63.51, for a total value of $1,270,200.00.
• On Wednesday, July 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $56.43, for a total value of $1,128,600.00.

Halozyme Therapeutics Stock Down 3.8%

Shares of NASDAQ:HALO opened at $68.98 on Monday. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. The stock has a fifty day simple moving average of $70.45 and a two-hundred day simple moving average of $61.93. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $79.50. The stock has a market capitalization of $8.07 billion, a price-to-earnings ratio of 15.78, a PEG ratio of 0.37 and a beta of 1.16.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.31. The firm had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company’s revenue was up 40.8% on a year-over-year basis. During the same period last year, the company earned $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Morgan Stanley upped their target price on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an “overweight” rating in a research note on Monday, August 18th. Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 5th. HC Wainwright lifted their target price on Halozyme Therapeutics from $85.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday. JMP Securities boosted their price target on Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a research note on Wednesday, August 6th. Finally, The Goldman Sachs Group started coverage on Halozyme Therapeutics in a research report on Thursday, July 10th. They set a “neutral” rating and a $55.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Hold” and an average price target of $70.44.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Wealth Preservation Advisors LLC purchased a new stake in shares of Halozyme Therapeutics during the first quarter worth about $32,000. Newbridge Financial Services Group Inc. purchased a new stake in Halozyme Therapeutics during the 2nd quarter valued at approximately $32,000. SVB Wealth LLC bought a new stake in shares of Halozyme Therapeutics during the first quarter valued at approximately $33,000. Bessemer Group Inc. lifted its holdings in shares of Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 207 shares in the last quarter. Finally, Employees Retirement System of Texas bought a new position in shares of Halozyme Therapeutics during the second quarter worth $34,000. Institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.